Pharmacogenomics and risk stratification in cardiovascular care: Insights from randomized controlled trials.

Genomics and personalized medicine are transforming cardiology by improving the assessment, diagnosis, and treatment of cardiovascular diseases (CVDs). To fully benefit from personalized cardiovascular care, future research should focus on validating genetic markers, refining risk prediction models, and overcoming barriers to widespread adoption.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 By understanding the genetic factors underlying CVDs, personalized treatment strategies can be developed to enhance patient outcomes and reduce the burden of cardiovascular conditions.
• 2 The integration of genomics into clinical practice enables more precise risk assessments, early detection, and targeted interventions.
• 3 This narrative review examines randomized clinical trials (RCTs) on genotype-guided therapies, pharmacogenomics, and personalized medicine in cardiology.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: